0.4556
Cytomx Therapeutics Inc stock is traded at $0.4556, with a volume of 2.04M.
It is down -16.11% in the last 24 hours and down -30.21% over the past month.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
See More
Previous Close:
$0.5431
Open:
$0.55
24h Volume:
2.04M
Relative Volume:
1.16
Market Cap:
$36.49M
Revenue:
$101.21M
Net Income/Loss:
$-569.00K
P/E Ratio:
-22.78
EPS:
-0.02
Net Cash Flow:
$-56.88M
1W Performance:
-27.48%
1M Performance:
-30.21%
6M Performance:
-60.38%
1Y Performance:
-77.88%
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
Name
Cytomx Therapeutics Inc
Sector
Industry
Phone
650.515.3185
Address
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Compare CTMX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
CTMX
Cytomx Therapeutics Inc
|
0.4556 | 36.49M | 101.21M | -569.00K | -56.88M | -0.02 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
May-28-24 | Upgrade | Piper Sandler | Neutral → Overweight |
May-09-24 | Upgrade | Wedbush | Neutral → Outperform |
May-06-24 | Upgrade | Jefferies | Hold → Buy |
Apr-22-24 | Upgrade | JP Morgan | Underweight → Neutral |
Nov-14-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Jul-07-22 | Downgrade | Jefferies | Buy → Hold |
Jul-07-22 | Downgrade | Mizuho | Buy → Neutral |
Jul-07-22 | Downgrade | Piper Sandler | Overweight → Neutral |
Jul-07-22 | Downgrade | Wedbush | Outperform → Neutral |
Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
Jan-18-22 | Upgrade | Barclays | Underweight → Overweight |
Nov-15-21 | Initiated | BTIG Research | Buy |
May-28-21 | Downgrade | Barclays | Equal Weight → Underweight |
Mar-29-21 | Initiated | JP Morgan | Overweight |
Mar-23-21 | Upgrade | Jefferies | Hold → Buy |
Sep-22-20 | Downgrade | Guggenheim | Buy → Neutral |
Jun-01-20 | Downgrade | Jefferies | Buy → Hold |
May-14-20 | Reiterated | H.C. Wainwright | Buy |
Mar-24-20 | Upgrade | Wedbush | Neutral → Outperform |
Mar-04-20 | Initiated | Barclays | Equal Weight |
Nov-20-19 | Initiated | Guggenheim | Buy |
Nov-11-19 | Downgrade | Wedbush | Outperform → Neutral |
Jun-13-19 | Initiated | Mizuho | Buy |
May-14-19 | Initiated | Cantor Fitzgerald | Overweight |
Mar-11-19 | Initiated | Barclays | Overweight |
Nov-26-18 | Initiated | Piper Jaffray | Overweight |
Oct-15-18 | Initiated | Goldman | Neutral |
Sep-13-18 | Initiated | H.C. Wainwright | Buy |
Jun-01-18 | Initiated | SunTrust | Buy |
Jan-05-18 | Initiated | Citigroup | Buy |
Sep-08-17 | Initiated | Wedbush | Outperform |
Mar-27-17 | Initiated | H.C. Wainwright | Buy |
Mar-02-17 | Initiated | Instinet | Buy |
Jan-03-17 | Downgrade | Oppenheimer | Outperform → Perform |
Nov-02-15 | Initiated | Oppenheimer | Outperform |
View All
Cytomx Therapeutics Inc Stock (CTMX) Latest News
CytomX stock hits 52-week low at $0.56 amid market challenges By Investing.com - Investing.com South Africa
CytomX stock hits 52-week low at $0.56 amid market challenges - Investing.com Australia
Analysts Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) Target Price at $5.02 - Defense World
Financial Metrics Check: CytomX Therapeutics Inc (CTMX)’s Ratios for Trailing Twelve Months - DWinneX
CytomX Therapeutics (NASDAQ:CTMX) Downgraded by StockNews.com to Hold - Defense World
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Shares Sold by Virtu Financial LLC - Defense World
StockNews.com Downgrades CytomX Therapeutics (NASDAQ:CTMX) to Hold - The AM Reporter
CytomX Therapeutics Faces Critical Challenges in Product Development and Market Viability - MSN
CytomX Therapeutics (CTMX) Upgraded to Strong Buy: Here's What You Should Know - MSN
CytomX therapeutics general counsel sells $6,111 in stock - Investing.com India
CytomX Therapeutics CMO Yu-Waye Chu sells shares for $2,410 By Investing.com - Investing.com Canada
Top Executives Cash Out: CytomX Therapeutics Stock Transactions Unveiled! - TipRanks
CytomX therapeutics CFO Christopher Ogden sells $5,122 in stock By Investing.com - Investing.com South Africa
CytomX Therapeutics CMO Yu-Waye Chu sells shares for $2,410 - Investing.com India
CytomX Therapeutics CEO sells $22,555 in stock By Investing.com - Investing.com South Africa
CytomX Therapeutics SVP Marcia Belvin sells $11,687 in stock - Investing.com India
CytomX Therapeutics SVP Marcia Belvin sells $11,687 in stock By Investing.com - Investing.com Canada
CytomX Therapeutics CEO sells $22,555 in stock - Investing.com India
CytomX Therapeutics Executives Sell Shares for Tax Obligations - TradingView
CytomX therapeutics CFO Christopher Ogden sells $5,122 in stock - Investing.com
CytomX therapeutics general counsel sells $6,111 in stock By Investing.com - Investing.com UK
CytomX Therapeutics’s SWOT analysis: biotech firm’s stock faces pivotal year By Investing.com - Investing.com Australia
CytomX at Barclays Healthcare: Probody Platform Progress By Investing.com - Investing.com South Africa
CytomX at Barclays Healthcare: Probody Platform Progress - Investing.com India
CytomX Therapeutics’s SWOT analysis: biotech firm’s stock faces pivotal year - Investing.com India
Are CytomX Therapeutics Inc (CTMX) shares a good deal now? - US Post News
CytomX Therapeutics (NASDAQ:CTMX) Upgraded by StockNews.com to “Buy” Rating - Defense World
What Are You Thinking About Investing In CytomX Therapeutics Inc (NASDAQ: CTMX) Stock? - stocksregister.com
CytomX Therapeutics’ (CTMX) Outperform Rating Reiterated at Wedbush - Defense World
Earnings call transcript: CytomX Therapeutics Q4 2024 reports strong revenue - Investing.com India
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Average Rating of “Moderate Buy” by Brokerages - Armenian Reporter
CytomX Therapeutics’ (CTMX) “Neutral” Rating Reiterated at HC Wainwright - Defense World
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q4 2024 Earnings Call Transcript - Insider Monkey
CytomX Therapeutics Full Year 2024 Earnings: Beats Expectations - Yahoo Finance
Analysts Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) Price Target at $5.77 - Defense World
CytomX Therapeutics’ Earnings Call Highlights Progress and Challenges - TipRanks
CytomX Therapeutics, Inc. (CTMX): Among the Cheap Growth Stocks to Buy Now - Insider Monkey
Deal Watch: Amgen, CytomX Pull Back On Part Of T-Cell Engager Collaboration - Citeline News & Insights
Cautious Outlook for CytomX Therapeutics Amid Pipeline Challenges and Strategic Setbacks - TipRanks
CytomX stock plunges to 52-week low, touches $0.6 By Investing.com - Investing.com Canada
CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update - The Manila Times
CytomX Therapeutics Inc (CTMX) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial Insights - GuruFocus.com
CytomX Therapeutics Inc (CTMX) Q4 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
CytomX Therapeutics Inc earnings beat by $0.43, revenue topped estimates - Investing.com South Africa
CytomX Therapeutics Inc (CTMX) Q4 2024 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada
CytomX Therapeutics Reports Strong 2024 Financial Results - TipRanks
Cytomx Therapeutics Inc Stock (CTMX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):